The US dollar has rallied rather significantly during the course of the trading session on Wednesday as we are now trying to break above the 50-day E ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Shares of Emera Inc. EMA shed 0.78% to C$56.09 Tuesday, in what proved to be an otherwise all-around favorable trading ...

Shares of Emera Inc. EMA were unchanged Wednesday, in what proved to be an all-around poor trading session for the Canadian market, with the S&P/TSX Composite Index GSPTSE falling 0.09% to 25,626.16.

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

Bisesero: A Daughter’s Story will recount the little-known true story of the Bisesero Resistance, in which tens of thousands ...

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

PayPal's competitive moat is not fully utilized and its payment and commerce ecosystems offer a wide range of growth ...

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like ...